Share your story and shine at JK Monitor!🌟 Welcome to JK Monitor, where every story matters and every achievement is celebrated! We invite you to share the remarkable journey of your life and showcase your accomplishments to the world. Join our exclusive interviews that honor exceptional individuals just like you. JAMMU: Venus Remedies Limited (NSE: VENUSREM, BSE: 526953), a leading research-driven pharmaceutical company, has once again received the World Health Organization (WHO) Good Distribution Practices (GDP) Certification for its Supply Chain Unit-II in Baddi, Himachal Pradesh, from Société Générale de Surveillance (SGS) — the world’s foremost inspection, testing, and certification authority.
Awarded basis a comprehensive audit, the certification underscores Venus Remedies’ unwavering commitment to global pharmaceutical quality norms and best practices in distribution. It highlights the company’s consistent adherence to international protocols across its end-to-end operations—from manufacturing to last-mile delivery.
“The WHO GDP certification is a strategic affirmation of our ability to deliver high-quality, safe, and effective medicines with precision, accountability, and transparency. Earned through a rigorous, independent audit, this recognition is a testament to our operational discipline, culture of continuous improvement, and the collective commitment of our teams to set new benchmarks for excellence in pharmaceutical delivery in India and globally,” said Mr. Saransh Chaudhary, President, Global Critical Care, Venus Remedies, and CEO, Venus Medicine Research Centre.
As part of its supply chain transformation, Venus Remedies has adopted a 360-degree digital logistics model, implementing IoT-enabled systems to monitor key shipment conditions—such as temperature, humidity, and location alerts—in real-time. The company has also developed proprietary warehousing algorithms to optimize cartonization and shipping workflows, halving delivery time while reducing costs.
Extending its reach directly to pharmacies and small retailers, Venus Remedies now operates a parallel online delivery system backed by real-time order tracking, digital payment reconciliation, and live customer support—strengthening its market presence and customer engagement in the country.
“At Venus Remedies, we believe that quality assurance must be embedded into every layer of operations—from R&D to real-time delivery. The WHO GDP accreditation validates our investment in cutting-edge logistics and reflects our strategic vision to be a globally trusted partner in healthcare,” said Mr. Peeyush Jain, Deputy Managing Director, Venus Remedies.
The company’s robust compliance credentials also include more than 25 Good Manufacturing Practices (GMP) certifications, including the most recent approval from Ukraine, for its globally benchmarked manufacturing facilities. Together with WHO GDP, these recognitions underscore Venus Remedies’ unwavering commitment to quality, safety, and regulatory integrity across every stage of the pharmaceutical value chain.
About Venus Remedies Ltd (venusremedies.com)
Panchkula-based Venus Remedies Ltd (NSE: VENUSREM, BSE: 526953) is among the 10 leading fixed-dosage injectable manufacturers in the world. Having a commercial presence in 90+ countries with a portfolio of 75 products spread over Europe, Australia, Africa, Asia-Pacific, Commonwealth States, the Middle East, Latin America and the Caribbean region, the company has nine globally benchmarked facilities in Panchkula, Baddi and Werne (Germany), apart from 11 overseas marketing offices. The company holds the GMP approvals from European- GMP (INFARMED), PIC/S (Malaysia & Ukraine), SAHPRA, UNICEF, TGA, INVIMA & WHO-GMP, alongside key ISO certifications for quality, environmental, and occupational health and safety management.
Central to its mission, Venus Remedies is a frontrunner in combating antimicrobial resistance (AMR) through its dedicated research division, Venus Medicine Research Centre (VMRC). The company is pivotal in developing advanced antibiotics and β-lactam/β-lactamase inhibitor combinations aimed at tackling multidrug-resistant pathogens. Its notable initiatives like GASAR provide essential data on antibiotic resistance, while the PLEA Trust fosters antibiotic stewardship. As an influential member of the AMR Industry Alliance, India AMR Innovation Hub, and Vivli AMR Registry, Venus Remedies shapes global AMR research and policy. Through strategic collaborations with academic and health organizations worldwide, the company enhances AMR surveillance and supports innovative drug development, affirming its leadership in global healthcare.
